Literature DB >> 25057190

Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.

Harpreet Sidhu1, Lorraine E Dansie1, Peter W Hickmott2, Douglas W Ethell3, Iryna M Ethell4.   

Abstract

Fmr1 knock-out (ko) mice display key features of fragile X syndrome (FXS), including delayed dendritic spine maturation and FXS-associated behaviors, such as poor socialization, obsessive-compulsive behavior, and hyperactivity. Here we provide conclusive evidence that matrix metalloproteinase-9 (MMP-9) is necessary to the development of FXS-associated defects in Fmr1 ko mice. Genetic disruption of Mmp-9 rescued key aspects of Fmr1 deficiency, including dendritic spine abnormalities, abnormal mGluR5-dependent LTD, as well as aberrant behaviors in open field and social novelty tests. Remarkably, MMP-9 deficiency also corrected non-neural features of Fmr1 deficiency-specifically macroorchidism-indicating that MMP-9 dysregulation contributes to FXS-associated abnormalities outside the CNS. Further, MMP-9 deficiency suppressed elevations of Akt, mammalian target of rapamycin, and eukaryotic translation initiation factor 4E phosphorylation seen in Fmr1 ko mice, which are also associated with other autistic spectrum disorders. These findings establish that MMP-9 is critical to the mechanisms responsible for neural and non-neural aspects of the FXS phenotype.
Copyright © 2014 the authors 0270-6474/14/349867-13$15.00/0.

Entities:  

Keywords:  dendritic spines; extracellular matrix; fragile X syndrome; hippocampus; mTOR signaling; matrix metalloproteinase

Mesh:

Substances:

Year:  2014        PMID: 25057190      PMCID: PMC4107404          DOI: 10.1523/JNEUROSCI.1162-14.2014

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  87 in total

Review 1.  Casting a net on dendritic spines: the extracellular matrix and its receptors.

Authors:  Lorraine E Dansie; Iryna M Ethell
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

2.  Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.

Authors:  C A Hoeffer; E Sanchez; R J Hagerman; Y Mu; D V Nguyen; H Wong; A M Whelan; R S Zukin; E Klann; F Tassone
Journal:  Genes Brain Behav       Date:  2012-02-15       Impact factor: 3.449

3.  Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.

Authors:  Sarah E Rotschafer; Michael S Trujillo; Lorraine E Dansie; Iryna M Ethell; Khaleel A Razak
Journal:  Brain Res       Date:  2011-12-31       Impact factor: 3.252

4.  Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits.

Authors:  M Uutela; J Lindholm; V Louhivuori; H Wei; L M Louhivuori; A Pertovaara; K Akerman; E Castrén; M L Castrén
Journal:  Genes Brain Behav       Date:  2012-04-11       Impact factor: 3.449

5.  EphB receptors trigger Akt activation and suppress Fas receptor-induced apoptosis in malignant T lymphocytes.

Authors:  Alison Maddigan; Luke Truitt; Ryan Arsenault; Tanya Freywald; Odette Allonby; Jonathan Dean; Aru Narendran; Jim Xiang; Andrew Weng; Scott Napper; Andrew Freywald
Journal:  J Immunol       Date:  2011-10-28       Impact factor: 5.422

Review 6.  Extracellular matrix molecules, their receptors, and secreted proteases in synaptic plasticity.

Authors:  Jakub Wlodarczyk; Irina Mukhina; Leszek Kaczmarek; Alexander Dityatev
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

Review 7.  MMP9: a novel function in synaptic plasticity.

Authors:  Magdalena Dziembowska; Jakub Wlodarczyk
Journal:  Int J Biochem Cell Biol       Date:  2012-02-09       Impact factor: 5.085

8.  Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.

Authors:  Aubin Michalon; Michael Sidorov; Theresa M Ballard; Laurence Ozmen; Will Spooren; Joseph G Wettstein; Georg Jaeschke; Mark F Bear; Lothar Lindemann
Journal:  Neuron       Date:  2012-04-12       Impact factor: 17.173

9.  PI3K contributed to modulation of spinal nociceptive information related to ephrinBs/EphBs.

Authors:  Li-Na Yu; Xue-Long Zhou; Jing Yu; Hao Huang; Li-Shan Jiang; Feng-Jiang Zhang; Jun-Li Cao; Min Yan
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

10.  Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.

Authors:  Jennifer A Ronesi; Katie A Collins; Seth A Hays; Nien-Pei Tsai; Weirui Guo; Shari G Birnbaum; Jia-Hua Hu; Paul F Worley; Jay R Gibson; Kimberly M Huber
Journal:  Nat Neurosci       Date:  2012-01-22       Impact factor: 24.884

View more
  89 in total

Review 1.  The Role of Proteases in Hippocampal Synaptic Plasticity: Putting Together Small Pieces of a Complex Puzzle.

Authors:  Ivan L Salazar; Margarida V Caldeira; Michele Curcio; Carlos B Duarte
Journal:  Neurochem Res       Date:  2015-11-07       Impact factor: 3.996

Review 2.  Pharmacological therapies for Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird
Journal:  Wien Med Wochenschr       Date:  2016-01-12

Review 3.  Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.

Authors:  Katarzyna Lepeta; Leszek Kaczmarek
Journal:  Schizophr Bull       Date:  2015-04-02       Impact factor: 9.306

4.  Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome.

Authors:  Jonathan W Lovelace; Maham Rais; Arnold R Palacios; Xinghao S Shuai; Steven Bishay; Otilia Popa; Patricia S Pirbhoy; Devin K Binder; David L Nelson; Iryna M Ethell; Khaleel A Razak
Journal:  Cereb Cortex       Date:  2020-03-14       Impact factor: 5.357

5.  Effect of MMP-9 gene knockout on retinal vascular form and function.

Authors:  Akash K George; Rubens P Homme; Avisek Majumder; Suresh C Tyagi; Mahavir Singh
Journal:  Physiol Genomics       Date:  2019-11-11       Impact factor: 3.107

6.  Metformin ameliorates core deficits in a mouse model of fragile X syndrome.

Authors:  Ilse Gantois; Arkady Khoutorsky; Jelena Popic; Argel Aguilar-Valles; Erika Freemantle; Ruifeng Cao; Vijendra Sharma; Tine Pooters; Anmol Nagpal; Agnieszka Skalecka; Vinh T Truong; Shane Wiebe; Isabelle A Groves; Seyed Mehdi Jafarnejad; Clément Chapat; Elizabeth A McCullagh; Karine Gamache; Karim Nader; Jean-Claude Lacaille; Christos G Gkogkas; Nahum Sonenberg
Journal:  Nat Med       Date:  2017-05-15       Impact factor: 53.440

Review 7.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 8.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 9.  Activity-dependent proteolytic cleavage of cell adhesion molecules regulates excitatory synaptic development and function.

Authors:  Sivapratha Nagappan-Chettiar; Erin M Johnson-Venkatesh; Hisashi Umemori
Journal:  Neurosci Res       Date:  2016-12-10       Impact factor: 3.304

Review 10.  Cell adhesion and invasion mechanisms that guide developing axons.

Authors:  Caitlin A Short; Edwin A Suarez-Zayas; Timothy M Gomez
Journal:  Curr Opin Neurobiol       Date:  2016-04-29       Impact factor: 6.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.